Complement C5a

Complement C5a 분자 정보

영어 이름Complement C5a시판 약물 수1
임상 약물 수2표적 별명C5a Complement,Complement 5a,Complement Component 5a
최고 연구 개발 단계Approved
영어 이름Complement C5a
표적 별명C5a Complement,Complement 5a,Complement Component 5a
시판 약물 수1
임상 약물 수2
최고 연구 개발 단계Approved

Complement C5a 제품 목록

  • 속성

    Protein (6)Kits (2)

  • 제품 라이브러리

    온라인 (8)

  • Human (4)Mouse (2)Cynomolgus (2)

  • 태그

    Tag Free (2)His Tag (3)Fc Tag (1)- (2)

  • 마커

    Unconjugated (6)- (2)

Complement C5a분자 배경

Complement component C5a (C5a) is a protein fragment generated upon cleavage of complement component C5. It is a potent chemotactic factor for human peripheral blood neutrophils and monocytes and is believed to play an important role in a number of inflammatory conditions. The major functions of C5a are as follows: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is an effective leukocyte chemoattractant, promoting the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing integrin avidity and upregulating the lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator and appears to be a key factor in the pathogenesis of many inflammatory diseases involving the complement system; and C5a modulates the balance between activating and inhibitory IgG Fc receptors on leukocytes, a mechanism that may enhance autoimmune responses under pathological conditions.

Complement C5a분자 별명

C5a,Complement Component 5a

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
BDB-001BDB-001; BDB001; BDB 001; BDB-1Phase 3 ClinicalStaidson(Beijing) Biopharmaceuticals Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa; Vasculitis
상세
STSA-1002STSA-1002; STSA1002Phase 3 ClinicalStaidson(Beijing) Biopharmaceuticals Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
VilobelimabIFX-1; CaCP-29ApprovedInflarx NvGohibicEURespiratory Distress Syndrome, AdultInflarx Nv, Inflarx Gmbh2025-01-13Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma, Squamous Cell; Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Granulomatosis with Polyangiitis; Hidradenitis Suppurativa; Microscopic Polyangiitis; Pyoderma Gangrenosum; Respiratory Distress Syndrome, Adult; Sepsis; Shock, Septic; Systemic Inflammatory Response Syndrome
상세

제품 리뷰

  • 1***52019-09-26
    0사람들이 좋아합니다
    I have ordered a lot of proteins from Acro. This one especially impressed me. Not only that they generously sent me the trial for my pre-experiment, but also they would develop different species of proteins that I need, which saved me a lot of time. Most importantly, ACRO not only does binding experiments, but also tests related functional assay. They even share them with customers. It is quite comprehensive. May all proteins come from you, ACRO.
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 제품 리뷰
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호